Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026GlobeNewsWire • 03/18/26
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including PyelonephritisGlobeNewsWire • 12/19/25
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business UpdateGlobeNewsWire • 11/13/25
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025GlobeNewsWire • 11/04/25
PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)GlobeNewsWire • 10/21/25
Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a TurnaroundZacks Investment Research • 08/19/25
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateGlobeNewsWire • 08/12/25
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025GlobeNewsWire • 08/05/25
Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsSeeking Alpha • 06/11/25
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study GoalZacks Investment Research • 05/29/25
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring CommitteeGlobeNewsWire • 05/28/25
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/13/25
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business UpdateGlobeNewsWire • 05/13/25
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025GlobeNewsWire • 05/05/25
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive OfficerGlobeNewsWire • 04/28/25
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/27/25
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business UpdateGlobeNewsWire • 03/27/25
Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025GlobeNewsWire • 03/18/25
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceGlobeNewsWire • 02/25/25